Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors.

ABSTRACT:

Background

Cutaneous immune-related adverse events (cirAEs) induced by immune checkpoint inhibitor (ICI) therapy share clinical features with spontaneous inflammatory dermatoses. However, the exact immunopathogenesis of cirAEs remains unclear.

Objective

To investigate the inflammation that mediates the most common cirAEs, lichenoid eruption (LE) and eczematous eruption (EE).

Methods

In a prospective cohort study, participants with cancer on ICI therapy with any clinically visible cirAEs were enrolled. T helper-1 (Th1) and Th2 cell responses in cirAEs were compared to spontaneous lichenoid dermatitis and eczematous dermatitis.

Results

Among 88 cirAE biopsies collected, LE (35.22%) and EE (31.81%) accounted for most cases. In contrast to lichenoid dermatitis, we

SUBMITTER: Azin M 

PROVIDER: S-EPMC12815391 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature